Two million capsules of Molnupiravir received by Thai Medical Services

14 Sept 04:09 Key points summarised by AI

The Thai Department of Medical Services acquired two million capsules (50,000 courses) of Molnupiravir, an anti-viral COVID-19 treatment, from Merck and Ridgeback Biotherapeutics.
The drug is designated for COVID-19 patients with mild to moderate symptoms and elderly patients with underlying diseases, but is not suitable for pregnant women or individuals with low white blood cell counts.
Distribution will prioritize hospitals in Bangkok due to higher infection rates, with one-third of the supply to be dispatched next week, aiming to reduce the risk of death if taken within five days of symptom onset.
This significant delivery coincides with Thailand reporting its highest-ever daily confirmed COVID-19 infections, underscoring the urgent need for effective treatments.

Thailand News in Brief